Veterinary Specialty Hospital - North County
Intra-articular Injection for the Treatment of Canine Elbow Dysplasia
OPEN
A new veterinary device composed of collagen and elastin particles has been developed; it has been shown to help protect cartilage from mechanical grinding. Previous anecdotal use of this product has been beneficial in dogs with elbow dysplasia.
Immunotherapy for Urothelial Carcinoma in Dogs
OPEN
Development of a safe and beneficial immunotherapy option for canine urothelial carcinoma patients will advance veterinarians' ability to treat this disease and will provide an important model to inform future canine and human clinical trials in this area.
Lung Tumor Fluid Dynamics Study
OPEN
Current chemotherapy treatments involve a direct injection into the tumor. We would like to use surgically removed lung tissue to better understand how drugs behave when they are injected into lung tumors in dogs, as well as humans, with lung tumors.
Methylnaltrexone (MNTX) Clinical Study
OPEN
This study seeks to define the rate at which methylnaltrexone (MNTX) is metabolized in dogs following intravenous administration. Postoperative regurgitation is a common side effect of general anesthesia. The opioid-inhibiting effects of MNTX block the risk of opioid-related complications, without reducing pain control and pain management.
Evaluation of Liver Protectants for Xylitol Toxicity in Dogs
OPEN
Xylitol is an artificial sweetener commonly found in sugar-free gum. Although safe for humans, xylitol is highly toxic to dogs. This study will compare the liver protective capacity of two veterinary liver protectant products in dogs suffering from xylitol toxicity.
Embolization of the Splenic Artery for Thrombocytopenia (eSPAT)
CLOSED
Immune-mediated thrombocytopenia (ITP) is a disorder characterized by severely low platelets due to attack by white blood cells. This is often associated with bruising and occasionally severe bleeding episodes.
Evaluating the Tolerability of Combination of Verdinexor and Doxorubicin in Dogs with Cancer
CLOSED
Verdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.
Metabolomics Trial to Evaluate for Systemic Consequences of Intestinal Dysbiosis
CLOSED
The intestinal microbiota are highly functional, with a combined genome (termed the microbiome) that is approximately 130-160 times larger than the human or canine genome. The microbiome is a highly functional organ and produces approximately 1,000 different metabolites, many of which have systemic effects in the dog.
ORBITS Clinical Study
OPEN
Despite years of active research in the field, high mortality rates associated with sepsis have remained unchanged over the last three decades; we aim to change this!
Minimally Invasive Metastasectomy in Canines (MIMIC)
OPEN
Following removal of the primary tumor and adjuvant chemotherapy, the development of lung metastasis is the most common cause of mortality in dogs with osteosarcoma. A distinctive feature of lung metastases of osteosarcoma in human patients is the surprising benefit that can result from surgical resection of the lung nodules. The use of surgery to manage osteosarcoma pulmonary metastases in dogs has been shown to be promising, but is not commonly used due to the presumed post-surgical morbidity of conventional thoracic surgery.
K9 Tumor And Blood Sampling for Osteosarcoma and Oral Melanoma (KABOOM)
OPEN
Naturally occurring cancers in dogs have been as used as models for human cancers for many reasons; however, the genomic profiles of many of these cancers are still incompletely understood. Further definition of these genomic landscapes will allow for improved development of novel diagnostics and therapeutics to diagnose and treat these cancers. The objective of this study is to develop cancer models of osteosarcoma and oral melanoma for use in future studies investigating the use of novel therapies.
Tolerability of Oral Paclitaxel in Cancer-Bearing Dogs
CLOSED
Research Type Ethos Discovery De Novo Study Description Paclitaxel is a human chemotherapeutic that has demonstrated a broad spectrum of activity against several human and canine cancers. Previous formulations of paclitaxel have been poorly absorbed in dogs, limiting its therapeutic value. Oraxol is a novel oral formulation of paclitaxel that is combined with a second drug, Encequidar, which improves this issue of poor absorption.
Ethos Precision Medicine Umbrella Study for Hemangiosarcoma (Ethos-PUSH)
OPEN
Is your dog undergoing surgery for a ruptured splenic tumor? Ethos Discovery would love to have you and your dog participate in our clinical trial! We are evaluating drugs for the treatment of HSA with the goal of curing this aggressive cancer.
DIABETIC Cat Study
CLOSED
We are investigating a new diet that has been shown to reduce body fat, maintain lean muscle mass, and eliminate the need for insulin in cats with newly diagnosed diabetes.
Collection of Biological Specimens from Dogs Scheduled for Biopsy or Surgery for Suspected or Known Cancer
CLOSED
This study will compare certain markers in the blood that are specific to cancer, but not found in healthy dogs, before and after surgical biopsy or surgical removal of a mass.
Collection of Biological Specimens from Dogs Diagnosed with Cancer, but Not Scheduled to Undergo Surgery for Tumor Removal
NO LONGER ENROLLING
This study will compare markers in the blood that are specific to cancer but not found in healthy dogs, before and after treatment for cancer has begun.
SEPSIS Clinical Study
OPEN
This study aims to evaluate changes in a specific blood hormone that has previously been related to sepsis diagnosis in canine patients surgically treated for sepsis in the abdomen and in healthy dogs with intestinal obstructions that are being surgically removed. We are investigating possible novel markers for sepsis with the goal of developing new diagnostic tests.
Dysbiosis Enhancing Linkage Towards Association with Canine Osteosarcoma (DEL-TACO Lite)
OPEN
This study aims to determine whether or not canine patients diagnosed with canine osteosarcoma (OSA) have intestinal dysbiosis and whether treating intestinal disease improves patient outcomes.
Rapamycin for the Treatment of Cancer in Dogs
OPEN
This study seeks to understand the intestinal absorption potential of a novel formulation of rapamycin when administered to dogs with naturally occurring cancer. The data from this study will be used to define an ideal dose of the drug to use in future cancer clinical studies.
